Could time of day boost cancer treatment power?
NCT ID NCT07251582
Summary
This study is testing whether the time of day a patient receives immunotherapy affects how well it shrinks their tumor before surgery. Patients with stage II-III non-small cell lung cancer will receive standard pre-surgery treatment and be randomly assigned to get their immunotherapy infusions either in the morning or the afternoon. The main goal is to see if one timing leads to more patients having no detectable cancer cells left at the time of their surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESECTABLE STAGE II-III NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hunan Cancer hospital
RECRUITINGChangsha, Hunan, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hunna Cancer Hospital, Clinical Trails Center
RECRUITINGChangsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.